| A real‐world analysis of migraine: A cross‐sectional study of disease burden and treatment patterns JH Ford, J Jackson, G Milligan, S Cotton, J Ahl, SK Aurora Headache: The Journal of Head and Face Pain 57 (10), 1532-1544, 2017 | 111 | 2017 |
| Clinical characteristics and treatment patterns among patients diagnosed with cluster headache in US healthcare claims data CK Choong, JH Ford, AW Nyhuis, SG Joshi, RL Robinson, SK Aurora, ... Headache: The Journal of Head and Face Pain 57 (9), 1359-1374, 2017 | 46 | 2017 |
| Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure DD Ruff, JH Ford, A Tockhorn-Heidenreich, M Sexson, S Govindan, ... Cephalalgia 39 (8), 931-944, 2019 | 41 | 2019 |
| Two randomized migraine studies of galcanezumab: effects on patient functioning and disability JH Ford, DW Ayer, Q Zhang, JN Carter, E Leroux, V Skljarevski, ... Neurology 93 (5), e508-e517, 2019 | 38 | 2019 |
| Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs JH Ford, K Schroeder, AW Nyhuis, SA Foster, SK Aurora Journal of Managed Care & Specialty Pharmacy 25 (1), 46-59, 2019 | 31 | 2019 |
| Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine JH Ford, SA Foster, VL Stauffer, DD Ruff, SK Aurora, J Versijpt Patient preference and adherence, 2413-2424, 2018 | 26 | 2018 |
| Societal burden of cluster headache in the United States: a descriptive economic analysis JH Ford, D Nero, G Kim, BC Chu, R Fowler, J Ahl, JM Martinez Journal of Medical Economics 21 (1), 107-111, 2018 | 25 | 2018 |
| Psychometric validation and meaningful within‐patient change of the Migraine‐Specific Quality of Life questionnaire version 2.1 electronic patient‐reported outcome in patients … RM Speck, R Yu, JH Ford, DW Ayer, R Bhandari, KW Wyrwich Headache: The Journal of Head and Face Pain 61 (3), 511-526, 2021 | 16 | 2021 |
| Economics of inhaled oxygen use as an acute therapy for cluster headache in the United States of America M O'Brien, JH Ford, SK Aurora, S Govindan, DE Tepper, SJ Tepper Headache: The Journal of Head and Face Pain 57 (9), 1416-1427, 2017 | 16 | 2017 |
| Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome RM Speck, H Shalhoub, DW Ayer, JH Ford, KW Wyrwich, EN Bush Journal of Patient-Reported Outcomes 3, 1-9, 2019 | 15 | 2019 |
| Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey JH Ford, W Ye, RM Nichols, SA Foster, DR Nelson Journal of medical economics 22 (9), 849-858, 2019 | 15 | 2019 |
| Health care utilization and direct costs among patients diagnosed with cluster headache in US health care claims data CK Choong, JH Ford, AW Nyhuis, RL Robinson, SK Aurora Journal of Managed Care & Specialty Pharmacy 24 (9), 921-928, 2018 | 12 | 2018 |
| A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe JH Ford, SA Foster, RM Nichols, A Tockhorn-Heidenreich, W Ye, ... Journal of Patient-Reported Outcomes 4, 1-11, 2020 | 11 | 2020 |
| Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials J Tobin, JH Ford, A Tockhorn-Heidenreich, RM Nichols, W Ye, R Bhandari, ... Journal of medical economics 25 (1), 630-639, 2022 | 8 | 2022 |
| Patient perspectives and experiences of preventive treatments and self-injectable devices for migraine: a focus group study J Seo, CA Smith, C Thomas, T Tervonen, A Hareendran, JH Ford, ... The Patient-Patient-Centered Outcomes Research, 1-16, 2022 | 8 | 2022 |
| Predicting initiation of preventive migraine medications: exploratory study in a large US medical claims database JH Ford, K Schroeder, DC Buse, S Joshi, S Gelwicks, SA Foster, ... Current Medical Research and Opinion 36 (1), 51-61, 2020 | 8 | 2020 |
| Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study JH Ford, VL Stauffer, P McAllister, S Akkala, M Sexson, DW Ayer, S Wang Quality of Life Research 30, 455-464, 2021 | 7 | 2021 |
| Migraine headache day response rates and the implications to patient functioning: an evaluation of 3 randomized phase 3 clinical trials of galcanezumab in patients with migraine JH Ford, T Kurth, AJ Starling, DW Ayer, LA Wietecha, MD Port, ... Headache: The Journal of Head and Face Pain 60 (10), 2304-2319, 2020 | 7 | 2020 |
| Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number … SA Foster, M Hoyt, W Ye, O Mason, JH Ford Current Medical Research and Opinion 38 (5), 653-660, 2022 | 6 | 2022 |
| Effects of galcanezumab on health-related quality of life and disability in patients with previous failure of 2–4 migraine preventive medication categories: results from a … SJ Tepper, J Ailani, JH Ford, RM Nichols, LQ Li, P Kemmer, AL Hand, ... Clinical Drug Investigation 42 (3), 263-275, 2022 | 5 | 2022 |
